NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
58 trialsNCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT01273610 2025-06-10
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00881621 2025-03-03
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT00470704 2024-12-19
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT00206427 2021-09-29
GW
Baylor Breast Care Center
Phase 2 Completed
NCT00883688 2020-08-26
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02362958 2020-07-15
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT00574171 2019-12-18
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
University of Wisconsin, Madison
Phase 2 Completed
NCT00820872 2019-10-21
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT00759642 2019-07-01
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
University of Kansas Medical Center
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT03225937 2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown
NCT01973660 2018-09-19
PAMELA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00225758 2018-07-27
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT02015169 2018-01-17
Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis
Samsung Medical Center
Phase 2 Completed
NCT02338245 2017-10-17
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
ASLAN Pharmaceuticals
Phase 2 Completed
NCT03273595 2017-09-06
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT01275859 2017-08-29
Neo-All-In
Asan Medical Center
Phase 2 Completed
NCT00721630 2017-08-15
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01934894 2017-07-02
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00246753 2017-06-28
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01868503 2017-06-26
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Stanford University
Phase 2 Terminated
NCT00482391 2017-05-12
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00496366 2017-03-21
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00490061 2017-03-06
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Stanford University
Phase 2 Terminated
NCT02342587 2017-02-17
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
Samsung Medical Center
Phase 2 Completed
NCT01769508 2016-06-13
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00973739 2016-03-22
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase 2 Completed
NCT01534455 2016-02-10
Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
GBG Forschungs GmbH
Phase 2 Terminated
NCT00769470 2016-01-22
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
Translational Oncology Research International
Phase 2 Completed
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT00343759 2015-12-11
Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
University of Pennsylvania
Phase 2 Withdrawn
NCT00694252 2015-09-28
Lapatinib and Circulating Tumor Cells in Breast Cancer
University Hospital of Crete
Phase 2 Completed
NCT00754702 2015-09-28
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
University Hospital of Crete
Phase 2 Terminated
NCT01161368 2015-08-13
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
Central European Cooperative Oncology Group
Phase 2 Terminated
NCT01218529 2014-12-31
Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01262469 2014-12-16
GERICO09
UNICANCER
Phase 2 Completed
NCT01666431 2014-12-03
Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment
University of Zurich
Phase 2 Terminated
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01145404 2014-07-02
GastroLap
National Center for Tumor Diseases, Heidelberg
Phase 2 Terminated
NCT00436644 2014-04-16
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Mayo Clinic
Phase 2 Completed
NCT01477060 2014-02-20
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
Fondazione Michelangelo
Phase 2 Terminated
NCT00903656 2013-12-24
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Terminated